Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by Analysts

Key Points

• Dianthus Therapeutics, Inc. has received a consensus rating of "Buy" from seven analysts, with an average 1-year price target of $54.00.
• The company reported a loss of ($0.88) EPS for the last quarter, missing the consensus estimate by $0.02, and had revenue significantly below expectations.
• Prominent hedge funds have increased their stakes in Dianthus Therapeutics, with institutional investors owning 47.53% of the company's stock.

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have earned an average recommendation of "Buy" from the seven brokerages that are covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have covered the stock in the last year is $54.00.

A number of research firms recently issued reports on DNTH. Wedbush raised their price target on Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a report on Thursday, August 21st. Robert W. Baird lowered their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. William Blair assumed coverage on shares of Dianthus Therapeutics in a report on Wednesday, July 2nd. They set an "outperform" rating for the company. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of DNTH. Hudson Bay Capital Management LP lifted its stake in shares of Dianthus Therapeutics by 53.9% in the second quarter. Hudson Bay Capital Management LP now owns 115,425 shares of the company's stock valued at $2,150,000 after purchasing an additional 40,425 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock worth $80,000 after purchasing an additional 3,317 shares during the last quarter. Vestal Point Capital LP grew its position in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the period. Rafferty Asset Management LLC increased its position in Dianthus Therapeutics by 19.5% during the second quarter. Rafferty Asset Management LLC now owns 28,522 shares of the company's stock worth $531,000 after purchasing an additional 4,650 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in Dianthus Therapeutics by 3,547.3% during the second quarter. BNP Paribas Financial Markets now owns 49,531 shares of the company's stock valued at $923,000 after acquiring an additional 48,173 shares during the period. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH traded up $0.40 during trading hours on Wednesday, hitting $24.66. The company had a trading volume of 348,965 shares, compared to its average volume of 324,647. The business has a 50 day moving average of $20.96 and a 200-day moving average of $20.06. The company has a market cap of $793.81 million, a PE ratio of -7.59 and a beta of 1.46. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. Sell-side analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.